Affinity DataIC50: 36nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Affinity DataIC50: 43nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Affinity DataIC50: 43nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics
US Patent
Propellon Therapeutics
US Patent
Affinity DataIC50: 49nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Affinity DataIC50: 54nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Affinity DataIC50: 75nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Affinity DataIC50: 106nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Affinity DataIC50: 111nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Affinity DataIC50: 174nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Affinity DataIC50: 182nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase 2A/Retinoblastoma-binding protein 5/Set1/Ash2 histone methyltransferase complex subunit ASH2/WD repeat-containing protein 5(Homo sapiens (Human))
China Pharmaceutical University
Curated by ChEMBL
China Pharmaceutical University
Curated by ChEMBL
Affinity DataIC50: 190nMAssay Description:Inhibition of recombinant MLL1/ASH2L/RBBP5/WDR5 complex histone methyltransferase activity (unknown origin) by AlphaScreen assayMore data for this Ligand-Target Pair
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics
US Patent
Propellon Therapeutics
US Patent
Affinity DataIC50: 197nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics
US Patent
Propellon Therapeutics
US Patent
Affinity DataIC50: 203nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Affinity DataIC50: 213nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics
US Patent
Propellon Therapeutics
US Patent
Affinity DataIC50: 216nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Affinity DataIC50: 272nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Affinity DataIC50: 272nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics
US Patent
Propellon Therapeutics
US Patent
Affinity DataIC50: 290nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics
US Patent
Propellon Therapeutics
US Patent
Affinity DataIC50: 293nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase 2A/Retinoblastoma-binding protein 5/Set1/Ash2 histone methyltransferase complex subunit ASH2/WD repeat-containing protein 5(Homo sapiens (Human))
China Pharmaceutical University
Curated by ChEMBL
China Pharmaceutical University
Curated by ChEMBL
Affinity DataIC50: 300nMAssay Description:Inhibition of His-SUMO-fused MLL1 (3762 to 3969 residues) interaction with His-SUMO-fused ASH2L/RBBP5/WDR5 (23 to 334 residues) (unknown origin) expr...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase 2A/Retinoblastoma-binding protein 5/Set1/Ash2 histone methyltransferase complex subunit ASH2/WD repeat-containing protein 5(Homo sapiens (Human))
China Pharmaceutical University
Curated by ChEMBL
China Pharmaceutical University
Curated by ChEMBL
Affinity DataIC50: 300nMAssay Description:Inhibition of recombinant SUMO-fused MLL1/ASH2L/RBBP5/WDR5 complex histone methyltransferase activity (unknown origin) expressed in Escherichia coli ...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase 2A/Retinoblastoma-binding protein 5/Set1/Ash2 histone methyltransferase complex subunit ASH2/WD repeat-containing protein 5(Homo sapiens (Human))
China Pharmaceutical University
Curated by ChEMBL
China Pharmaceutical University
Curated by ChEMBL
Affinity DataIC50: 300nMAssay Description:Inhibition of recombinant MLL1/ASH2L/RBBP5/WDR5 complex histone methyltransferase activity (unknown origin) by AlphaScreen assayMore data for this Ligand-Target Pair
Affinity DataIC50: 316nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics
US Patent
Propellon Therapeutics
US Patent
Affinity DataIC50: 332nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Affinity DataIC50: 380nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase 2A/Retinoblastoma-binding protein 5/Set1/Ash2 histone methyltransferase complex subunit ASH2/WD repeat-containing protein 5(Homo sapiens (Human))
China Pharmaceutical University
Curated by ChEMBL
China Pharmaceutical University
Curated by ChEMBL
Affinity DataIC50: 400nMAssay Description:Inhibition of His-SUMO-fused MLL1 (3762 to 3969 residues) interaction with His-SUMO-fused ASH2L/RBBP5/WDR5 (23 to 334 residues) (unknown origin) expr...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase 2A/Retinoblastoma-binding protein 5/Set1/Ash2 histone methyltransferase complex subunit ASH2/WD repeat-containing protein 5(Homo sapiens (Human))
China Pharmaceutical University
Curated by ChEMBL
China Pharmaceutical University
Curated by ChEMBL
Affinity DataIC50: 400nMAssay Description:Inhibition of recombinant SUMO-fused MLL1/ASH2L/RBBP5/WDR5 complex histone methyltransferase activity (unknown origin) expressed in Escherichia coli ...More data for this Ligand-Target Pair
Affinity DataIC50: 467nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Affinity DataIC50: 478nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics
US Patent
Propellon Therapeutics
US Patent
Affinity DataIC50: 514nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics
US Patent
Propellon Therapeutics
US Patent
Affinity DataIC50: 529nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics
US Patent
Propellon Therapeutics
US Patent
Affinity DataIC50: 549nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics
US Patent
Propellon Therapeutics
US Patent
Affinity DataIC50: 592nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics
US Patent
Propellon Therapeutics
US Patent
Affinity DataIC50: 592nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics
US Patent
Propellon Therapeutics
US Patent
Affinity DataIC50: 607nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Affinity DataIC50: 620nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase 2A/Retinoblastoma-binding protein 5/Set1/Ash2 histone methyltransferase complex subunit ASH2/WD repeat-containing protein 5(Homo sapiens (Human))
China Pharmaceutical University
Curated by ChEMBL
China Pharmaceutical University
Curated by ChEMBL
Affinity DataIC50: 750nMAssay Description:Inhibition of recombinant MLL1/ASH2L/RBBP5/WDR5 complex histone methyltransferase activity (unknown origin) by AlphaScreen assayMore data for this Ligand-Target Pair
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics
US Patent
Propellon Therapeutics
US Patent
Affinity DataIC50: 764nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Affinity DataIC50: 774nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics
US Patent
Propellon Therapeutics
US Patent
Affinity DataIC50: 779nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Affinity DataIC50: 780nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Affinity DataIC50: 820nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Affinity DataIC50: 864nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Affinity DataIC50: 885nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase 2A/Retinoblastoma-binding protein 5/Set1/Ash2 histone methyltransferase complex subunit ASH2/WD repeat-containing protein 5(Homo sapiens (Human))
China Pharmaceutical University
Curated by ChEMBL
China Pharmaceutical University
Curated by ChEMBL
Affinity DataIC50: 900nMAssay Description:Inhibition of recombinant MLL1 (unknown origin) interaction with recombinant ASH2L/RBBP5/WDR5 (unknown origin) assessed as decrease in histone methyl...More data for this Ligand-Target Pair
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics
US Patent
Propellon Therapeutics
US Patent
Affinity DataIC50: 907nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics
US Patent
Propellon Therapeutics
US Patent
Affinity DataIC50: 939nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics
US Patent
Propellon Therapeutics
US Patent
Affinity DataIC50: 939nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics
US Patent
Propellon Therapeutics
US Patent
Affinity DataIC50: 939nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics
US Patent
Propellon Therapeutics
US Patent
Affinity DataIC50: 966nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
